NICE Bites No 99 July/August 2017 from North West Medicines Information Centre includes one topic: Parkinson’s disease in adults. It includes the following sections: Assessment and diagnosis, information and support, treatment and management, motor symptoms, non-motor symptoms, adverse effects, palliative care.
Issue 8 of the bulletin: Controlled Drugs: Learning from Incidents, produced by NECS on behalf of NHS England is now available.
Issue 8 covers:
• Reporting incidents
• Post-dated CD prescriptions dispensed too early
• Patients with protected addresses
• Midazolam injection for palliative care
• What can happen when things go wrong when prescribing for chronic pain
The MHRA have issued information on central serous chorioretinopathy, a retinal disorder that has been linked to the systemic use of corticosteroids. Recently, it has also been reported after local administration of corticosteroids via inhaled and intranasal, epidural, intra-articular, topical dermal, and periocular routes.
Healthcare professionals should advise patients to report any blurred vision or other visual disturbances during corticosteroid treatment and consider referral to an ophthalmologist for evaluation of possible causes if a patient presents with vision problems.
The Medicines and Healthcare products Regulatory Agency (MHRA) has reclassified the antimalarial Maloff Protect (atovaquone/proguanil hydrochloride) to make it available from a pharmacist without a prescription.
Maloff Protect will be sold at pharmacies after a discussion with the pharmacist. They will be made available to adults aged over 18, weighing more than 40kg, travelling to areas affected by malaria and where the malaria parasite is not resistant to the Maloff Protect ingredients.